VTRS
Viatris·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 3
Consensus Rating "Strong Buy"
Significant Net Income Decline
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VTRS
Viatris Inc.
A global healthcare company that develops generic and branded drugs for a diverse range of treatments from cardiovascular health to oncology
1000 Mylan Boulevard, Canonsburg, Pennsylvania, 15317
--
Viatris Inc., was incorporated in Delaware on February 14, 2019. The company is a global healthcare company that believes they are uniquely positioned to bridge the traditional divide between generic drugs and brands, combining the best of both to more fully meet healthcare needs on a global scale. Viatris's mission is to empower people around the world to live healthier lives at every stage of life, provide access services on a large scale, currently provide high-quality medicines to about 1 billion patients worldwide every year, and touch all the moments of life, from birth to the end of life, from acute to chronic diseases.
Earnings Call
Q1/2025
Estimate EPS0.49
Actual EPS0.5
Estimate Revenue3.24B
Actual Revenue3.25B
Viatris Q1 2025: Unraveling Contradictions on Indore Remediation, Meloxicam Sales, and Revenue Targets
May 20,2025 12:26
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.56
Actual EPS0.62
Estimate Revenue3.46B
Actual Revenue3.57B
Viatris Q2 2025: Unraveling Contradictions in Tariffs, Growth Strategies, and Market Opportunities
Aug 07,2025 11:13
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
VTRS has released its 2025 Q3 earnings. EPS was reported at 0.67, versus the expected 0.62, beating expectations. The chart below visualizes how VTRS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VTRS has released its 2025 Q3 earnings report, with revenue of 3.76B, reflecting a YoY change of 0.23%, and net profit of -128.20M, showing a YoY change of -235.23%. The Sankey diagram below clearly presents VTRS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
